178242-93-8Relevant articles and documents
PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
-
Paragraph 0253, (2015/06/17)
There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I'): (in the above-mentioned general formula (I'), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.
Synthesis and structure-activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors
Gilmore, John L.,King, Bryan W.,Harris, Cathy,Maduskuie, Thomas,Mercer, Stephen E.,Liu, Rui-Qin,Covington, Maryanne B.,Qian, Mingxin,Ribadeneria, Maria D.,Vaddi, Krishna,Trzaskos, James M.,Newton, Robert C.,Decicco, Carl P.,Duan, James J.-W.
, p. 2699 - 2704 (2007/10/03)
A novel series of achiral TNF-α converting enzyme (TACE) inhibitors has been discovered. These compounds exhibited activities from 0.35 to 11 nM in a porcine TACE assay and inhibited TNF-α production in an LPS-stimulated whole blood assay with an IC5
Novel 5-hydroxytryptamine 4 (5-HT4) receptor agonists. Synthesis and gastroprokinetic activity of 4-amino-N-[2-(1-aminocycloalkan-1-yl)ethyl]-5- chloro-2-methoxybenzamides
Suzuki, Takeshi,Imanishi, Naoki,Itahana, Hirotsune,Watanuki, Susumu,Miyata, Keiji,Ohta, Mitsuaki,Nakahara, Hideaki,Yamagiwa, Yoko,Mase, Toshiyasu
, p. 1116 - 1124 (2007/10/03)
A novel series of 4-amino-N-[2-(1-aminocycloalkan-1-yl)ethyl]-5-chloro- 2-methoxybenzamide derivatives (1), which had amines conformationally restricted due to the effect of repulsion by neighboring substituents, were prepared and evaluated for 5-hydroxytryptamine 4 (5-HT4) agonistic activities by using the contraction of longitudinal muscle myenteric plexus (LMMP) of guinea pig ileum. One of the most potent compounds in this series was 4-amino-5-chloro-N-[2-(1-dimethylamino-1-cyclohexyl)ethyl]-2- methoxybenzamide (1c, YM-47813) with an EC50 value of 1.0 μM on LMMP. This compound effectively enhanced gastric motility and gastric emptying in conscious dogs by oral administration (1-3 mg/kg).